INmune Bio (NASDAQ:INMB) Stock Rating Lowered by Wall Street Zen

INmune Bio (NASDAQ:INMB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, INmune Bio has a consensus rating of “Moderate Buy”.

INmune Bio Price Performance

Shares of INMB stock opened at $1.13 on Friday. INmune Bio has a fifty-two week low of $1.06 and a fifty-two week high of $2.60. The firm’s 50 day moving average price is $1.88 and its two-hundred day moving average price is $1.63. The stock has a market cap of $31.59 million, a price-to-earnings ratio of -1.88 and a beta of 0.97.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Institutional Investors Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. Bank of New York Mellon Corp purchased a new position in INmune Bio in the 2nd quarter valued at about $35,000. Russell Investments Group Ltd. grew its stake in shares of INmune Bio by 64.0% during the third quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock valued at $49,000 after acquiring an additional 9,850 shares in the last quarter. Focus Partners Advisor Solutions LLC purchased a new stake in shares of INmune Bio during the second quarter worth about $71,000. GSA Capital Partners LLP purchased a new stake in shares of INmune Bio during the second quarter worth about $134,000. Finally, Ieq Capital LLC purchased a new stake in shares of INmune Bio during the second quarter worth about $134,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.